New RPS Fellows: November 2025
Published: 25 November 2025
This was published when the organisation was the Royal Pharmaceutical Society.
The Royal Pharmaceutical Society Panel of Fellows has designated the following 17 members as Fellows of the Royal Pharmaceutical Society for Distinction in the Profession of Pharmacy:
- Mari Beddis
- Shani Corb
- Ciara Duffy
- Naomi Fleming
- Janet Gilbertson
- Roz Gittins
- Nirusha Govender
- Ryan Hamilton
- Nazir Hussain
- Nicholas Kaye
- Ross MacRae
- Antonio Ochoa-Ferraro
- Bhavisa Pattani
- Oksana Pyzik
- Bethan Tranter
- Nicola Tyers
- Caroline Watson
Being appointed a Fellow of the Royal Pharmaceutical Society is one of the highest accolades that can be paid to a member.
It recognises the distinction members have attained in a particular aspect or aspects of their pharmacy career. As Fellowships are based on nominations from members, it also signifies the high esteem in which members are held by their peers.
The Society currently has 833 Fellows from across the profession representing a variety sectors and career stages.
View the full list of Fellows which can be searched by alphabet. Please note those in the list above will appear on this list shortly.
Read more RCPharm news stories.
Related news
Limit nasal decongestant spray use to seven days, says RPS
Nasal decongestant sprays should be used for no more than seven days, the RPS has warned, after new data showed many patients are unaware that longer use can trigger rebound congestion and dependence.
Call for evidence on facilitated self-selection of P medicines
This news story was published when the organisation was the Royal Pharmaceutical Society. We've published a call for evidence on the facilitated self-selection of P medicines following changes made by the regulator, the General Pharmaceutical Council (GPhC), enabling more pharmacies to adopt this practice. The call for evidence is open for eight weeks from 12 July – 06 September 2024 and is the outcome of the national Pharmacy Boards meeting in June, which discussed the current RPS position that "Pharmacy medicines must not be accessible to the public by self-selection", as stated in our guide Medicines, Ethics and Practice. The Call asks for submission of evidence of the benefits and harms of a facilitated self-selection model for P medicines in relation to patient care, and any evidence gaps with an explanation of areas where further research is required. RPS CEO Paul Bennett said: "Following changes brought by the GPhC focusing on an outcomes approach to standards, they have confirmed they no longer prohibit facilitated self-selection of P medicines. As a result, there are pharmacies that are now adopting a more flexible interpretation to providing this group of medicines. "The GPhC have stated that sale and supply of a P medicine must still take place in a registered pharmacy premises under the supervision of a pharmacist, and that appropritae measures should be in place to ensure that supervision continues. "The evidence base gathered through this exercise will inform a report by RPS Science and Research to enable us to consider our current position. As the professional body, we are committed to patient safety and the safe development of innovative practice to meet the needs of patients now and for the future. Please share the call for evidence with your networks." To inform the review, we want to hear from a wide range of pharmacists and pharmacy team members, patient representative bodies, employers, academics, think tanks, pharmacy representative bodies, regulators and other stakeholders and researchers. Please read and respond to the call for evidence.